Resistance to Inhibitors of the Human Immunodeficiency Virus Type 1 Integration

Overview

Journal Braz J Infect Dis

Specialty Infectious Diseases

Date 2011 Jan 12

PMID 21221483

Citations 10

Authors

Daria J Hazuda

Affiliations

Soon will be listed here.

Abstract

This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection.

Citing Articles

Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco.

Alaoui N, El Alaoui M, Touil N, Annaz H, Melloul M, Tagajdid R BMC Res Notes. 2018; 11(1):369.

PMID: 29884219 PMC: 5994051. DOI: 10.1186/s13104-018-3492-5.

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.

Doyle T, Dunn D, Ceccherini-Silberstein F, de Mendoza C, Garcia F, Smit E J Antimicrob Chemother. 2015; 70(11):3080-6.

PMID: 26311843 PMC: 4613743. DOI: 10.1093/jac/dkv243.

Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.

Hassounah S, Mesplede T, Quashie P, Oliveira M, Sandstrom P, Wainberg M J Virol. 2014; 88(17):9683-92.

PMID: 24920794 PMC: 4136349. DOI: 10.1128/JVI.00947-14.

The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance.

Wainberg M Scientifica (Cairo). 2013; 2012:238278.

PMID: 24278679 PMC: 3820659. DOI: 10.6064/2012/238278.

Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.

Quashie P, Mesplede T, Han Y, Veres T, Osman N, Hassounah S Antimicrob Agents Chemother. 2013; 57(12):6223-35.

PMID: 24080645 PMC: 3837891. DOI: 10.1128/AAC.01835-13.